<DOC>
	<DOCNO>NCT00784303</DOCNO>
	<brief_summary>The purpose study determine safety efficacy oral E7080 medullary iodine-131 refractory , unresectable differentiate thyroid cancer .</brief_summary>
	<brief_title>Evaluating Safety Efficacy Oral E7080 Medullary Iodine-131 Refractory , Unresectable Differentiated Thyroid Cancers , Stratified Histology</brief_title>
	<detailed_description>This open-label study approximately 50 study center US , Europe country . The study consist screen period ( Pre-Treatment Phase ) , 28-day treatment cycle ( Treatment Phase ) , study termination/final visit survival follow-up . Patients show clinical benefit continue receive study drug ( Extension Phase ) follow appropriate assessment .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must histologically cytologically confirm diagnosis Medullary Thyroid Cancer ( MTC ) Differentiated Thyroid Cancer ( DTC ) . 2 . Measurable disease meeting follow criterion : 1 . At least one lesion ( ≥ 1.5 cm long diameter nonlymph node ≥2.0 cm long diameter lymph node ) serially accurately measurable accord Modified Response Evaluation Criteria Solid Tumors ( RECIST ) use either compute tomography ( CT ) magnetic resonance imaging ( MRI ) 2 . Lesions electron beam radiotherapy must show evidence progressive disease base Modified Response Evaluation Criteria Solid Tumors ( RECIST ) deem target lesion 3 . Patients must show evidence disease progression Response Evaluation Criteria Solid Tumors ( RECIST ) use site assessment compute tomography/magnetic resonance imaging ( CT/MRI ) scan within 12 month ( +1 month allow variance patient scan interval ) prior study entry . 4 . Patients Differentiated Thyroid Cancer ( DTC ) must 131I refractory/resistant : never demonstrate 131I uptake , progression despite 131I uptake , cumulative dose 131I &gt; 600 mCi ( last dose give least 6 month prior study entry ) . 5 . Well controlled blood pressure prior study entry . 6 . Signed informed consent . Exclusion criterion : 1 . Anaplastic thyroid carcinoma , thyroid lymphoma , mesenchymal tumor thyroid , metastases thyroid . 2 . Brain leptomeningeal metastasis . 3 . Significant cardiovascular impairment ( history congestive heart failure &gt; New York Heart Association [ NYHA ] Class II , unstable angina myocardial infarction within 6 month study start , serious cardiac arrhythmia ) . 4 . Marked baseline prolongation QT/QTc interval . 5 . Proteinuria &gt; 1+ &gt; 30 mg dipstick test . 6 . Active hemoptysis ( bright red blood least ½ teaspoon ) 28 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Thyroid Cancer</keyword>
</DOC>